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Background: A small literature suggests that pharmacotherapy may be useful in the prophylaxis of posttraumatic
stress disorder in patients presenting with major trauma. There is relatively little data, however, on the use of
selective serotonin reuptake inhibitors (SSRIs) in this context.
Methods: 24 week, double-blind placebo controlled study. 31 participants presenting immediately after trauma,
and meeting diagnostic criteria for full or partial acute stress disorder were randomized to treatment with
10–20 mg of escitalopram or placebo daily for 24 weeks. 2 participants were excluded from the analysis due to early
drop out, leaving 29 participants (escitalopram = 12, placebo = 17) for inclusion in an intent- to- treat analysis.
Participants were followed up until 56 weeks, and assessed with the Clinician Administered PTSD Scale (CAPS).
A mixed model repeated measures analysis of variance (RMANOVA) was undertaken to determine the efficacy of
the intervention on the CAPS score.
Results: There was a significant reduction in CAPS score over the course of treatment (F(7, 142) = 41. 58, p < 0.001)
in both the escitalopram and placebo groups, with a greater reduction in CAPS score in the placebo group
F(7, 142) = 2.12, p = 0.045. There were improvements on all secondary measures, including the Clinical Global
Impressions scale, and scales assessing depression, anxiety and disability. Only functional disability outcomes
(F(7, 141) = 2.13, p = .04), were significantly different between treatment and placebo groups. In the sample as a
whole, improvement in scores were maintained at the 52 week follow-up. Side effects were comparable between
the groups.
Conclusions: These data are consistent with other recent work indicating that the SSRIs may not be efficacious in
the prevention of PTSD. Nevertheless, the small sample size and baseline differences between groups limit the
explanatory power of the study. Although a consideration of the possibility of medication prophylaxis in PTSD
remains important, both from conceptual and clinical perspectives, caution is needed with regards to the use of
SSRIs until their efficacy can be proven.
Trial registration: Clinical Trials NCT00300313
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Post-traumatic stress disorder (PTSD) is a chronic and
debilitating condition that can have profound effects on
functioning (work-place, family and social), and severely
compromise quality of life. Community studies have sug-
gested that at least 50% of adults will encounter a trau-
matic event in the course of their lifetime [1-3], while* Correspondence: sharain@sun.ac.za
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unless otherwise stated.lifetime community prevalence rates of PTSD range from
an average of 1.9% in Europe to 6.8% in the USA [4,5].
The psychological treatment with the best evidence for
efficacy in treating and preventing PTSD is trauma-
focused cognitive behaviour therapy (TF-CBT) [6-8]. As
such clinical guidelines currently recommend TF-CBT as
the treatment of choice for PTSD [9].
With regard to medication treatment, a number of
randomized controlled trials (RCTs) have found that se-
lective serotonin re-uptake inhibitors (SSRIs) are effective
in reducing PTSD and its associated symptoms [10-13].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PTSD [14] concluded that SSRIs are effective in treating
PTSD in both the short and longer term. Although SSRIs
are accepted first-line pharmacotherapy for acute and
chronic PTSD [15,16], little is known about their use in
the prevention of PTSD [17].
Two studies have addressed whether a SSRI, taken after
exposure to a traumatic event, may reduce the risk for de-
velopment of PTSD after an acute stress reaction. First, in
an animal model of PTSD, injection of a SSRI, 1 hour after
exposure to a traumatic event, reduced anxiety-like and
avoidant behavior, decreased hyper-arousal response and
significantly diminished the incidence of PTSD-like re-
sponse [18]. The second study, an RCT of escitalopram
for acute PTSD [19], found no positive effect of the drug
over placebo or wait-list controls.
Further studies are needed to determine whether the
early administration of PTSD prophylaxis, i.e. SSRIs, ad-
ministered shortly after trauma exposure is efficacious for
individuals with severe symptomatology. Further research
is also needed to determine the optimal window for ad-
ministration of medications used prophylactically [20].
Objectives
The primary objectives of the study were to determine
the efficacy of escitalopram in preventing PTSD in
trauma-exposed participants with Acute Stress Disorder
(ASD), and to determine its efficacy in reducing PTSD
symptoms. The secondary objectives were to determineAssessed for
Analysed (n=12) 
Lost to follow-up (not contactable) (n=1) 
Allocated to intervention (n=13) 
Random
Figure 1 Flow diagram of procedures.if escitalopram was efficacious in the prevention and im-
provement of depression and self-reported anxiety, de-
pression and disability in trauma exposed participants
with ASD.
Methods
Study design
This was a prospective, randomized, double-blind pla-
cebo controlled trial of escitalopram in the prevention of
PTSD symptoms in traumatized adults with full or par-
tial ASD.
Sample
31 participants who met the following criteria were in-
cluded in the study: (i) experience of a traumatic event,
such as a vehicle collision or other accident, physical or
sexual assault within the previous 4 weeks; (ii) between
18 and 65 years of age; (iii) sufficient knowledge of Eng-
lish in order to read, understand and sign the Informed
Consent form as well as study procedures and assess-
ment instruments; (iv) presence of either full DSM-IV
criteria or intrusion and hyper-arousal criteria for ASD.
Two participants (one from each treatment group) were
excluded prior to the first post-baseline assessment and
analysis as they were not contactable. The sample thus
comprised of 12 participants on escitalopram and 17 on
placebo (Figure 1).
Exclusion criteria comprised (i) refusal of any medi-
cation therapy; (ii) serious physical injury at inclusion eligibility (n=38) 
Excluded (n=7) 
Declined to participate (n= 4) 
Other reasons (n= 3) 
Lost to follow-up (not contactable) (n=1) 
Allocated to control (n=18) 
Analysed (n= 17) 
ized (n=31) 
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(iii) concomitant medications not allowed in the study
(monoamine oxidase inhibitors [MAOIs], reversible in-
hibitors of monoamine oxidase A [RIMAs], mood stabi-
lisers, antipsychotics or psychoactive herbal remedies
within the 3 weeks prior to screening, anxiolytics or se-
rotonergic agonists within the 2 weeks prior to screen-
ing, treatment with any anticonvulsant drug); lifetime
DSM-IV-TR criteria for mania or bipolar disorder, schizo-
phrenia, any personality disorder, mental retardation or
pervasive developmental disorder, or cognitive disorder;
significant suicide risk and/or a score of ≥5 on item
10 of the Montgomery Asberg Depression Rating Scale
(MADRS) scale; history of severe suicide attempt; elec-
troconvulsive therapy within the last year; currently
serving in the South African security forces.; history of
drug allergy or hypersensitivity to escitalopram or cita-
lopram; illness severe enough to prevent participation
in the study (including liver or renal insufficiency; car-
diovascular, pulmonary, gastrointestinal, endocrine (in-
cluding uncontrolled thyroid), neurological (including
epilepsy), infectious, neoplastic, or metabolic disturbances;
pregnant or breast-feeding; refusal of adequate contracep-
tive use (if female).
Procedures
Approval for the study was obtained from the University
of Cape Town, Faculty of Health Sciences Human Re-
search Ethics Committee (HREC ref: 221/2006), as well
as from hospitals and clinics where recruitment took
place. The study was conducted in accordance with the
Declaration of Helsinki, and informed consent was ob-
tained from all participants.
Eligible participants were recruited from University of
Cape Town (UCT) affiliated hospitals (Groote Schuur, G
F Jooste, Gugulethu Day Hospital, Vanguard Community
Health Clinic) and were randomly allocated to one of
the two treatment groups (active or placebo) according
to a computer-generated randomization list. Randomi-
zation numbers were assigned consecutively. Escitalo-
pram (10 mg) and placebo were supplied as capsules of
identical appearance. Medication was supplied in wallet
cards that were dispensed at each visit. Wallet cards
were identified by visit (i.e., visit 2, visit 3, etc.) with the
escitalopram and placebo packed by the study pharma-
cist in sequentially numbered identical blister packs. Par-
ticipants and investigators were blinded to treatment
allocation and there were no instances of un-blinding.
Enrolled participants were dispensed wallet cards at
each visit after visit 2 (baseline/ week 0) and instructed to
take one capsule of 10 mg escitalopram, or placebo, which
was titrated up to 20 mg per day at week 4, orally. A de-
crease in dose, back to one capsule of 10 mg, or placebo,
was permitted for intolerable side effects. Participantswere instructed to return the blister pack and all unused
medication at their next visit. Investigators noted whether
or not the pack was returned and if any medication
remained in the participant’s file. Participants were also
asked whether they had been compliant since the previous
visit. Noncompliance resulted in that participant being
withdrawn from the study.
Assessments were conducted every 2 weeks until visit
8 (week 12) and thereafter every 4 weeks. At each as-
sessment, rating scales were administered and concomi-
tant medication use and adverse events noted.
Measures
-The essential features of ASD, and whether full or par-
tial, were recorded according to DSM-IV criteria.
-Demographics details: sex, age, number of years of edu-
cation, and, socioeconomic status.
-Trauma characteristics: type of event, event characteris-
tics (evaluated by the PTSD Diagnostic Scale (PDS) [21].
-Physical condition: evaluated using the Abbreviated In-
jury Scale (AIS) [22].
-The following psychiatric rating scales were also used:
Primary measure:
Clinician Administered PTSD Scale (CAPS):
The CAPS [23] consists of 17 items that cover the core
symptoms of PTSD according to the DSM-IV criteria.
Eight additional items are included to measure the fre-
quency and intensity of features frequently associated
with PTSD. In addition, the CAPS includes five global
rating scales that reflect the impact of symptoms on so-
cial and occupational functioning, general severity, any
recent changes in severity, and the assessor’s evaluation
of the validity of the participant’s report.
For each of the 17 items, the interviewer rates each of
the frequency and the intensity of the symptoms on a 5
point scale rated from 0–4. A total score (ranges be-
tween 0–272) is calculated by summing the frequency
and intensity scores for each item. A score of ≥50 indi-
cates PTSD. The CAPS can also be scored according to
the DSM diagnostic criteria for PTSD, rendering a di-
chotomous rating of the presence or absence of PTSD.
Secondary measures:
Clinical Global Impression Scales (CGI):
The CGI scales [24] consist of two separate scales:
Clinical Global Impression – Severity (CGI-S) and Cli-
nical Global Impression – Improvement (CGI-I). Both
scales are rated from 1–7. The investigator uses his/her
total clinical experience with this patient population to
judge symptom severity at the time of rating (CGI-S).
At follow-up overall improvement is rated (CGI-I).
Mini International Neuropsychiatric Interview (MINI
5.0.0):
The MINI [25] is a brief, structured diagnostic inter-
view for clinical and research settings. It has a total of
Suliman et al. BMC Psychiatry  (2015) 15:24 Page 4 of 8120 questions that cover 17 current and past DSM-IV
Axis I disorders.
Montgomery-Asberg Depression Rating Scale (MADRS):
The MADRS [26] is a depression rating scale consis-
ting of 10 items that represent the core symptoms
of depressive illness. The rating is based on a clinical
interview with the participant, moving from broadly
phrased questions about symptoms to more detailed
ones, which allows a precise rating of severity, covering
the last 7 days. The clinician who conducts the rating
must decide whether the rating lies on the defined scale
steps (0, 2, 4, 6) or between them (1, 3, 5), on a scale
ranging from 0–60.
Visual Analogue Scale for Depression (VAS-D):
The VAS-D [27] is a self-rating scale, designed to as-
sess depression severity, from a subjective point of view.Table 1 Baseline demographic and descriptive details of
participants
Total sample (N = 29) Escitalopram
(N = 12)
Placebo
(N = 17)
Significance
Gender
Male: 19 N = 7 N = 12
Female: 10 N = 5 N = 5 p = 0 .50
Age (mean ± SD in years)
29.52 ± 8.17 31.33 ± 7.85 28.24 ± 8.38 p = 0.32
Ethnicity*
Black African: 23 N = 12 N = 11
Coloured/Mixed race: 6 N = 0 N = 6 p = 0.03
Education
(mean ± SD in years)
9.38 ± 2.27 9.25 ± 2.18 10.06 ± 2.82 p = 0.41
Employment
Yes: 16 N = 6 N = 10
No: 13 N = 6 N = 7 p = 0.64
Annual income
(mean ± SD)
$26190 ± 14483 30625 ± 14253 23462 ± 4489 p = 0.28
AIS
Minor: 9 N = 5 N = 4
Moderate: 11 N = 3 N = 8
Serious: 8 N = 4 N = 4 p = 0.86
Trauma types
Assault
(physical/sexual): 20
N = 10 N = 10
Other (mva/witnessing
event): 9
N = 2 N = 7 p = 0.15
AIS: Acute Injury Scale; ASD: Acute Stress Disorder; mva: motor vehicle
accident; SD: standard deviation.
*p < 0.05.
Note: numbers may not add up to 100% due to missing data.The responder is required to indicate how depressed s/he
is, on a scale ranging from 0–10.
Visual Analogue Scale for Anxiety (VAS-A):
The VAS-A [27] is a self-rating scale, designed to as-
sess anxiety, from a subjective point of view. The re-
sponder is required to indicate how anxious s/he feels,
on a scale ranging from 0–10.
Sheehan Disability Scale (SDS):
The SDS [28] is a 3-item self-rating scale of functional
impairment. The items address the impact of symptoms
of PTSD on three areas of functioning, namely, work,
social, and family within the last 7 days.
Data analyses
Data were captured for all visits where PTSD was as-
sessed with the CAPS (weeks 0, 4, 12, 24, 32, 40, 48 and
56/ visits 2, 4, 8, 11, 13, 15, 17, 19). Demographic and
baseline data were compared using chi-square/Fisher’s
exact tests or analysis of variance (ANOVA). Assessment
of PTSD prevention was based on the CAPS total score.
The mean change from baseline (visit 2/week 0) to theTable 2 Baseline clinical details of participants
Total sample (N = 29) Escitalopram
(N = 12)
Placebo
(N = 17)
Significance
ASD
Full: 27 N = 12 N = 15
Partial: 2 N = 0 N = 2 p = 0.39
Any MINI disorder
Yes: 19 N = 7 N = 12
No: 10 N = 5 N = 5 p = 0.50
CAPS PTSD
Yes: 15 N = 4 N = 11
No: 14 N = 8 N = 6 p = 0.09
CAPS (mean ± SD)
55.10 ± 23.50 45.33 ± 21.43 62.00 ± 22.98 p = 0.06
CGI-S (mean ± SD)
3.24 ± 0.87 3.08 ± 0.10 3.35 ± 0.79 p = 0.35
MADRS (mean ± SD)
14.79 ± 9.56 11.92 ± 9.42 16.82 ± 9.40 p = 0.05
VAS-D (mean ± SD)
4.45 ± 2.65 3.75 ± 2.60 4.94 ± 2.66 p = 0.24
VAS-A (mean ± SD)
5.22 ± 2.16 5.33 ± 2.19 5.15 ± 2.21 p = 0.82
SDS (mean ± SD)
12.10 ± 7.65 8.83 ± 6.46 14.41 ± 7.75 p = 0.05
CAPS: Clinician Administered PTSD Scale; CGI-S: Clinical Global Impressions
Scale- severity; MADRS: MINI: MINI International Neuropsychiatric Interview;
Montgomery Asberg Depression Rating Scale; SD: standard deviation;
SDS: Sheehan Disability Scale; VAS-D: Visual Analogue Scale-Depression;
VAS-A: Visual Analogue Scale- Anxiety.
Note: numbers may not add up to 100% due to missing data.
F(7, 142)=2.1181, p=.04533
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Figure 2 Change in PTSD severity score across study time points.
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outcome measure. Using an intent-to-treat sample, de-
fined as all participants with at least one post-baseline
CAPS assessment, efficacy for escitalopram vs. placebo
was tested using a mixed model repeated measures analysis
of variance (RMANOVA). The mixed model approach al-
lows for patients with incomplete data to be included and
utilizes the data that is available for all patients. General-
ised Estimating Equation (GEE) models were used for cat-
egorical outcomes. Rates of PTSD were determined by the
cut off of 50 points on the CAPS. Maintenance efficacy
was determined by the change in CAPS scores betweenFigure 3 Number of participants with PTSD at each study time point.weeks 24 and 56. Improvement on secondary outcome
measures were also evaluated. CGI-responders were de-
fined as those with CGI-I scores of 2 (much improved) or
1 (very much improved) at week 24. All tests were two-
tailed with p-values <0.05 considered significant. Frequen-
cies of the most common adverse events are tabled and
reported if present in more than one subject in either
of the study groups.
Results
The baseline demographic and clinical details of the 29
participants included in the study are listed in Tables 1
Table 3 Change in scores across treatment and follow-up period (mean ± SE)
Start (week 2) to end (week 24) of treatment End of treatment (week 24) to 6 month follow-up (week 56)
Escitalopram Placebo Escitalopram Placebo
CAPS −29.29(±4.76)** −44.11(±3.81)** −5.85(±6.98) −7.69(±4.22)
CGI-S −1.41(±0.20)** −1.50(±0.16)** −0.36(±0.22) −0.18(±0.17)
CGI-I −1.60 (±0.70) −1.75 (±1. 70) −1.00 (±0.00) −1.42 (±0.52)
MADRS −8.62(±1.94)** −11.99(±1.55)** −1.59(±2.24) −1.10(±1.72)
VAS-D −2.17(±0.61)** −2.89(±0.49)** −0.57(±0.70) −0.18(±0. 45)
VAS-A −2.81(±0.72)** −2.63(±0.54)** −0.32(±0.77) −1.01(±0.60)
SDS −5.58(±1.58)** −8.25(±1.26)** −1.96(±1.82) −1.16(±1.40)
CAPS: Clinician Administered PTSD Scale; CGI-I: Clinical Global Impressions Scale- improvement; MADRS: Montgomery Asberg Depression Rating Scale; SDS:
Sheehan Disability Scale; SE: Standar Error; VAS-D: Visual Analogue Scale- Depression; VAS-A: Visual Analogue Scale- Anxiety; *: p < 0.05; **: p < 0.01.
Table 4 Number of patients with adverse events
Adverse event Escitalopram Placebo
Increased appetite 2 1
Rash/itch 0 2
Drowsiness 2 2
Stomach upset/cramps 2 3
Sweating 2 1
Dizziness 1 1
Insomnia 1 1
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the majority having experienced assault (physical or sex-
ual assault: N = 20), and the remainder having been in a
motor vehicle accident or been witness to a traumatic
life event (N = 9).The only significant demographic dif-
ference between the escitalopram and placebo groups
was with regards to ethnicity, as there were no coloured/
mixed race people in the escitalopram group. When we
left people of colour (N = 6) out of the analyses, however,
results were not much different. The placebo group had
higher CAPS and MADRS scores and reported greater
disability at baseline, with differences trending towards
significance. On the MINI the most commonly reported
disorders at baseline were current depression (N = 10)
and PTSD (N = 14). Suicidality (N = 9), other anxiety dis-
orders (N = 6), alcohol dependence or abuse (N = 5) and
antisocial personality disorder (N = 1) were also reported.
There was a significant reduction in CAPS scores over
the course of treatment (F(7, 142) = 41. 58, p ≤ 0.01) in
both the escitalopram and placebo groups, in favour of
the placebo group F(7, 142) = 2.12, p ≤ 0.01 (Figure 2).
Thirty-three percent of participants in the escitalopram
group met criteria for PTSD (CAPS score of 50 ≥) at
baseline, all of whom were in remission by week 4 of
treatment. This was maintained until the end of the
follow-up period. Sixty-five percent of participants in the
placebo group initially met criteria for PTSD. This num-
ber dropped to 6% at the end of treatment and was 6%
at the end of the follow-up period (Figure 3). We were
unable to perform GEE for PTSD incidence as the num-
ber of participants with PTSD was too low at the follow-
up assessments.
CGI-S reduced significantly (F(7, 140) = 43.09, p ≤ 0.01),
but there was no difference between treatment and pla-
cebo groups (F(7, 140) = 0.50, p = 0.83). On the CGI-I, 22
participants (75.9% of the sample) were classified as re-
sponders by the end of treatment, all of whom retained
their responder status at 52-weeks. Based on the CGI-I, 9
subjects (75.0%) in the escitalopram group and 13 (76.5%)in the placebo group were “much improved” or “very
much improved” at the end of the treatment phase.
There was a reduction of symptoms in all other im-
pairment, depression and anxiety measures across the
treatment period (p ≤ 0.01) which was maintained at the
52-week follow-up (Table 3). With the exception of func-
tional impairment, as measured by the SDS, (F(7, 41) =
15.27, p = 0.04), there were also no significant differences
(p > 0.05) between the escitalopram and placebo groups
on symptom severity using secondary outcome measures.
The number of participants meeting criteria for Any MINI
diagnosis in each group also reduced across the trial, and
almost reached significance (χ2 = 7.52 (3), p = 0.06), with
similar reductions in both groups (χ2 = 0.30 (3), p = 0.96).
Adverse events are listed in Table 4. There were no
significant group differences in the incidence of adverse
events. The most commonly reported were stomach
cramps/upset (n = 5), drowsiness (N = 4), sweating (N = 3)
and increased appetite (N = 3). Due to side effects, dosage
was reduced to 10 mg in 1 participant in the escitalopram
group. Adherence to treatment was acceptable in both
groups, with only 2 participants in each group withdrawn.
Discussion
The main finding of this study was that escitalopram
was not more efficacious than placebo in reducing PTSD
symptoms on the CAPS. There were also no differences
Suliman et al. BMC Psychiatry  (2015) 15:24 Page 7 of 8in secondary outcomes of anxiety and depression. Func-
tional impairment/disability scores, however, did reduce
significantly more in the placebo group than in the esci-
talopram group. These findings are consistent with the
work of Shalev and colleagues [19], who found that sub-
jects on escitalopram did not experience greater improve-
ment in symptoms than those who received placebo, and
in fact fared worse at the 9-month assessment. Our results
could, however, be an effect of regression to the mean
given that the placebo group showed a trend towards sig-
nificantly worse PTSD and depressive symptoms, as well
as functional impairment, at baseline.
Several limitations should be noted. Most important is
the group differences mentioned above, which limit the
explanatory power of the study. A matching procedure
would potentially have avoided these pre-existing differ-
ences between groups. The second is the relatively small
sample size. Thirdly, subjects here are not necessarily
representative of those with PTSD in the broader commu-
nity, given that they were physically injured, hospitalized
subjects, who were all highly symptomatic at inclusion.
Fourth, participants were not matched on trauma type or
ethnicity. Nonetheless, trauma type did not differ between
groups and the exclusion of participants of mixed race
from the analysis (as there were none in the escitalopram
group) did not alter results.
Conclusion
From a practical perspective, it seems premature to rec-
ommend the use of SSRIs in PTSD prophylaxis, given
that both this study and that of Shalev and colleagues
[19] did not find evidence of efficacy. Even so, given the
small sample sizes in both studies, there is insufficient
data to make a conclusive determination about the effi-
cacy of SSRIs. Despite small randomized controlled trials
of other pharmaco-prophylactic interventions (e.g. pro-
pranolol, hydrocortisone and gabapentin) not demonstra-
ting unequivocal evidence of efficacy [20], with current
investigations under way into the psychobiology of PTSD
and the discovery of novel prophylactic targets, there is
hope that efficacious preventive medications will be
found [29].
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